Open-Label, Randomized Study to Evaluate the Influence on the Hormonal and Ovarian Activity of Two Different Dosages of Drospirenone (either 4.0 mg for 24 Days or 2.8 mg Daily for 28 Days) Over Two Treatment Cycles in 50 Healthy, Young Females
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2012
At a glance
- Drugs Drospirenone (Primary)
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Leon Farma
- 26 May 2012 Actual end date 17 Apr 2012 added as reported by European Clinical Trials Database.
- 26 May 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 18 Nov 2011 New trial record